March 29, 2016
After tentatively green-lighting investors' claims earlier this year that Arrowhead Research Corp. overstated Hepatitis B vaccine trial results, a California federal judge tossed the proposed class action on Tuesday, saying the suit was too thin on specifics.
January 05, 2016
A California judge on Tuesday tentatively refused to dismiss a putative shareholder class action against Arrowhead Research Corp. over claims that the biopharmaceuticals maker misled investors about the progress of human trials for its hepatitis B vaccine, inflating its stock.